Rivaroxaban (Xarelto) for the indication 'treatment of pulmonary embolism'

The WAR has approved a pharmacotherapeutic report for the medicine rivaroxaban (Xarelto®) 15 mg tablet for oral use. In determining its therapeutic value, it was compared with enoxaparin (a low molecular weight heparin) in combination with warfarin or acenocoumarol (vitamin K antagonists). They reached the following conclusion:
the therapeutic value of rivaroxaban for the treatment of pulmonary embolism in adults is equivalent to that of enoxaparin/acenocoumarol.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.